Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Hypervirulent Klebsiella pneumoniae.

Russo TA, Marr CM.

Clin Microbiol Rev. 2019 May 15;32(3). pii: e00001-19. doi: 10.1128/CMR.00001-19. Print 2019 Jun 19. Review.

PMID:
31092506
2.

Aerobactin Synthesis Proteins as Antivirulence Targets in Hypervirulent Klebsiella pneumoniae.

Russo TA, Gulick AM.

ACS Infect Dis. 2019 Apr 29. doi: 10.1021/acsinfecdis.9b00117. [Epub ahead of print]

PMID:
31032610
3.

Antibody Dependent Enhancement of Acinetobacter baumannii Infection in a Mouse Pneumonia Model.

Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Russo TA, Balthasar JP.

J Pharmacol Exp Ther. 2019 Mar;368(3):475-489. doi: 10.1124/jpet.118.253617. Epub 2019 Jan 3.

PMID:
30606761
4.

Hypervirulent Klebsiella pneumoniae: a new public health threat.

Marr CM, Russo TA.

Expert Rev Anti Infect Ther. 2019 Feb;17(2):71-73. doi: 10.1080/14787210.2019.1555470. Epub 2018 Dec 5. No abstract available.

PMID:
30501374
5.

Mechanical stretch implications for vascular endothelial cells: Altered extracellular matrix synthesis and remodeling in pathological conditions.

Russo TA, Stoll D, Nader HB, Dreyfuss JL.

Life Sci. 2018 Nov 15;213:214-225. doi: 10.1016/j.lfs.2018.10.030. Epub 2018 Oct 18.

PMID:
30343127
6.

Controls on nitrogen transformation rates on restored floodplains along the Cosumnes River, California.

Hoagland B, Schmidt C, Russo TA, Adams R, Kaye J.

Sci Total Environ. 2019 Feb 1;649:979-994. doi: 10.1016/j.scitotenv.2018.08.379. Epub 2018 Aug 29.

PMID:
30179826
7.

Identification of Biomarkers for Differentiation of Hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae.

Russo TA, Olson R, Fang CT, Stoesser N, Miller M, MacDonald U, Hutson A, Barker JH, La Hoz RM, Johnson JR.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00776-18. doi: 10.1128/JCM.00776-18. Print 2018 Sep.

8.

Getting hypervirulent Klebsiella pneumoniae on the radar screen.

Sellick JA, Russo TA.

Curr Opin Infect Dis. 2018 Aug;31(4):341-346. doi: 10.1097/QCO.0000000000000464. Review.

PMID:
29847328
9.

Mechanism-Based Disease Progression Model Describing Host-Pathogen Interactions During the Pathogenesis of Acinetobacter baumannii Pneumonia.

Diep JK, Russo TA, Rao GG.

CPT Pharmacometrics Syst Pharmacol. 2018 Aug;7(8):507-516. doi: 10.1002/psp4.12312. Epub 2018 Aug 24.

10.

Molecular Epidemiology of Extraintestinal Pathogenic Escherichia coli.

Johnson JR, Russo TA.

EcoSal Plus. 2018 Apr;8(1). doi: 10.1128/ecosalplus.ESP-0004-2017. Review.

PMID:
29667573
11.

Acute Pyelonephritis in Adults.

Johnson JR, Russo TA.

N Engl J Med. 2018 Mar 22;378(12):1162. doi: 10.1056/NEJMc1801800. No abstract available.

PMID:
29562155
12.

Acute Pyelonephritis in Adults.

Johnson JR, Russo TA.

N Engl J Med. 2018 Jan 4;378(1):48-59. Review. No abstract available. Erratum in: N Engl J Med. 2018 Mar 15;378(11):1069.

PMID:
29298155
13.

The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.

Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Balthasar JP, Russo TA.

Infect Immun. 2017 Nov 17;85(12). pii: e00591-17. doi: 10.1128/IAI.00591-17. Print 2017 Dec.

14.

Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.

Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, Hsieh S, Yeshoua B, Pascual B, Vinogradov E, Hujer KM, Domitrovic TN, Bonomo RA, Russo TA, Lesczcyniecka M, Schneider T, Spellberg B.

J Infect Dis. 2017 Aug 15;216(4):489-501. doi: 10.1093/infdis/jix315.

15.

Metabolite Transporter PEG344 Is Required for Full Virulence of Hypervirulent Klebsiella pneumoniae Strain hvKP1 after Pulmonary but Not Subcutaneous Challenge.

Bulger J, MacDonald U, Olson R, Beanan J, Russo TA.

Infect Immun. 2017 Sep 20;85(10). pii: e00093-17. doi: 10.1128/IAI.00093-17. Print 2017 Oct.

16.

Negative Effect of Acoustic Panels on Listening Effort in a Classroom Environment.

Amlani AM, Russo TA.

J Am Acad Audiol. 2016 Nov/Dec;27(10):805-815.

PMID:
27885976
17.

Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.

Diep JK, Jacobs DM, Sharma R, Covelli J, Bowers DR, Russo TA, Rao GG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02121-16. doi: 10.1128/AAC.02121-16. Print 2017 Feb.

18.

The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii.

Russo TA, Manohar A, Beanan JM, Olson R, MacDonald U, Graham J, Umland TC.

mSphere. 2016 May 11;1(3). pii: e00082-16. doi: 10.1128/mSphere.00082-16. eCollection 2016 May-Jun.

19.

Crystal structure of 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase from the ESKAPE pathogen Acinetobacter baumannii.

Sutton KA, Breen J, Russo TA, Schultz LW, Umland TC.

Acta Crystallogr F Struct Biol Commun. 2016 Mar;72(Pt 3):179-87. doi: 10.1107/S2053230X16001114. Epub 2016 Feb 16.

20.

Burkholderia ginsengisoli bacteraemia: emergence of a novel pathogen.

Marks LR, Dodd H, Russo TA, Berenson CS.

BMJ Case Rep. 2016 Feb 24;2016. pii: bcr2015213584. doi: 10.1136/bcr-2015-213584.

21.

Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.

Russo TA, Spellberg B, Johnson JR.

J Infect Dis. 2016 Mar 15;213(6):901-3. doi: 10.1093/infdis/jiv533. Epub 2015 Nov 12. Review.

22.

Structure of shikimate kinase, an in vivo essential metabolic enzyme in the nosocomial pathogen Acinetobacter baumannii, in complex with shikimate.

Sutton KA, Breen J, MacDonald U, Beanan JM, Olson R, Russo TA, Schultz LW, Umland TC.

Acta Crystallogr D Biol Crystallogr. 2015 Aug;71(Pt 8):1736-44. doi: 10.1107/S139900471501189X. Epub 2015 Jul 31.

PMID:
26249354
23.

Optimisation of the Caenorhabditis elegans model for studying the pathogenesis of opportunistic Acinetobacter baumannii.

Vallejo JA, Beceiro A, Rumbo-Feal S, Rodríguez-Palero MJ, Russo TA, Bou G.

Int J Antimicrob Agents. 2015 Jul 9. pii: S0924-8579(15)00241-1. doi: 10.1016/j.ijantimicag.2015.05.021. [Epub ahead of print]

PMID:
26213382
24.

Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo.

Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA.

Infect Immun. 2015 Aug;83(8):3325-33. doi: 10.1128/IAI.00430-15. Epub 2015 Jun 8.

25.

Hypervirulent Klebsiella pneumoniae.

Patel PK, Russo TA, Karchmer AW.

Open Forum Infect Dis. 2014 Jun 2;1(1):ofu028. doi: 10.1093/ofid/ofu028. eCollection 2014 Mar.

26.

Re-evaluating the approach to drug target discovery in multidrug-resistant Gram-negative bacilli.

Umland TC, Schultz LW, Russo TA.

Future Microbiol. 2014;9(10):1113-6. doi: 10.2217/fmb.14.72. No abstract available.

27.

Assessment of Managed Aquifer Recharge Site Suitability Using a GIS and Modeling.

Russo TA, Fisher AT, Lockwood BS.

Ground Water. 2015 May-Jun;53(3):389-400. doi: 10.1111/gwat.12213. Epub 2014 Jun 10.

PMID:
24916466
28.

Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) Klebsiella pneumoniae.

Russo TA, Olson R, Macdonald U, Metzger D, Maltese LM, Drake EJ, Gulick AM.

Infect Immun. 2014 Jun;82(6):2356-67. doi: 10.1128/IAI.01667-13. Epub 2014 Mar 24.

29.

OxyR contributes to the virulence of a Clonal Group A Escherichia coli strain (O17:K+:H18) in animal models of urinary tract infection, subcutaneous infection, and systemic sepsis.

Johnson JR, Russo TA, Drawz SM, Clabots C, Olson R, Kuskowski MA, Rosen H.

Microb Pathog. 2013 Nov;64:1-5. doi: 10.1016/j.micpath.2013.07.001. Epub 2013 Jul 12.

PMID:
23850958
30.

Draft Genome Sequence of the Hypervirulent Klebsiella pneumoniae Strain hvKP1, Isolated in Buffalo, New York.

Russo TA, Gill SR.

Genome Announc. 2013 Mar 14;1(2):e0006513. doi: 10.1128/genomeA.00065-13.

31.

Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed.

Shon AS, Bajwa RP, Russo TA.

Virulence. 2013 Feb 15;4(2):107-18. doi: 10.4161/viru.22718. Epub 2013 Jan 9. Review.

32.

The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.

Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA.

Infect Immun. 2013 Mar;81(3):915-22. doi: 10.1128/IAI.01184-12. Epub 2013 Jan 7.

33.

In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media.

Umland TC, Schultz LW, MacDonald U, Beanan JM, Olson R, Russo TA.

MBio. 2012 Aug 31;3(4). pii: e00113-12. doi: 10.1128/mBio.00113-12. Print 2012.

34.

Hypervirulent Klebsiella pneumoniae: the next superbug?

Shon AS, Russo TA.

Future Microbiol. 2012 Jun;7(6):669-71. doi: 10.2217/fmb.12.43. No abstract available.

35.

Biofilm formed by a hypervirulent (hypermucoviscous) variant of Klebsiella pneumoniae does not enhance serum resistance or survival in an in vivo abscess model.

Kong Q, Beanan JM, Olson R, Macdonald U, Shon AS, Metzger DJ, Pomakov AO, Russo TA.

Virulence. 2012 May 1;3(3):309-18. doi: 10.4161/viru.20383. Epub 2012 May 1.

36.

Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection.

Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B.

PLoS One. 2012;7(1):e29446. doi: 10.1371/journal.pone.0029446. Epub 2012 Jan 10.

37.

Hypervirulent K. pneumoniae secretes more and more active iron-acquisition molecules than "classical" K. pneumoniae thereby enhancing its virulence.

Russo TA, Shon AS, Beanan JM, Olson R, MacDonald U, Pomakov AO, Visitacion MP.

PLoS One. 2011;6(10):e26734. doi: 10.1371/journal.pone.0026734. Epub 2011 Oct 24.

38.

Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant.

Pomakova DK, Hsiao CB, Beanan JM, Olson R, MacDonald U, Keynan Y, Russo TA.

Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):981-9. doi: 10.1007/s10096-011-1396-6. Epub 2011 Sep 15.

PMID:
21918907
39.

In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii.

Russo TA, Page MG, Beanan JM, Olson R, Hujer AM, Hujer KM, Jacobs M, Bajaksouzian S, Endimiani A, Bonomo RA.

J Antimicrob Chemother. 2011 Apr;66(4):867-73. doi: 10.1093/jac/dkr013. Epub 2011 Feb 13.

40.

The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.

Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA.

Infect Immun. 2010 Sep;78(9):3993-4000. doi: 10.1128/IAI.00366-10. Epub 2010 Jul 19.

41.

Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis.

Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox AD, St Michael F, Vinogradov EV, Campagnari AA.

Infect Immun. 2010 May;78(5):2017-23. doi: 10.1128/IAI.00016-10. Epub 2010 Mar 1.

42.

Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.

Naik NH, Russo TA.

Clin Infect Dis. 2009 Dec 1;49(11):1729-32. doi: 10.1086/648075.

PMID:
19886792
43.

High frequency of hotspot mutations in core genes of Escherichia coli due to short-term positive selection.

Chattopadhyay S, Weissman SJ, Minin VN, Russo TA, Dykhuizen DE, Sokurenko EV.

Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12412-7. doi: 10.1073/pnas.0906217106. Epub 2009 Jul 15.

44.

Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo.

Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald IJ, Sauberan SL, Luke NR, Schultz LW, Umland TC.

J Infect Dis. 2009 Feb 15;199(4):513-21. doi: 10.1086/596317.

PMID:
19143563
45.

Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine.

Russo TA, Beanan JM, Olson R, MacDonald U, Cope JJ.

Vaccine. 2009 Jan 14;27(3):388-95. doi: 10.1016/j.vaccine.2008.10.082. Epub 2008 Nov 17.

PMID:
19014988
46.

Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology.

Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA.

Infect Immun. 2008 Aug;76(8):3577-86. doi: 10.1128/IAI.00269-08. Epub 2008 Jun 9.

47.

Extraintestinal pathogenic isolates of Escherichia coli do not possess active IgA1, IgA2, sIgA or IgG proteases.

Russo TA, Carlino-MacDonald U.

FEMS Immunol Med Microbiol. 2008 Jun;53(1):65-71. doi: 10.1111/j.1574-695X.2008.00393.x. Epub 2008 Apr 1.

48.

Capsule and O-antigen from an extraintestinal isolate of Escherichia coli modulate cytokine levels in rat macrophages in vitro and in a rat model of pneumonia.

Russo TA, Davidson BA, Beanan JM, Olson R, Holm BA, Notter RH, Knight PR 3rd.

Exp Lung Res. 2007 Sep;33(7):337-56.

PMID:
17849261
49.

What you need to know before purchasing a PACS.

Mancino PB, Russo TA.

J Am Coll Radiol. 2007 Feb;4(2):92-6. No abstract available.

PMID:
17412238
50.

Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model.

Russo TA, Wang Z, Davidson BA, Genagon SA, Beanan JM, Olson R, Holm BA, Knight PR 3rd, Chess PR, Notter RH.

Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L632-43.

Supplemental Content

Loading ...
Support Center